- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00404378
Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]
September 11, 2017 updated by: GlaxoSmithKline
An Open-label, Two Period, Fixed Sequence Study of Healthy Subjects to Assess the Effect of Repeat Oral Dosing of Ketoconazole on the Pharmacokinetics of a Single Oral Dose of [GW679769]
This is a two period study of healthy adult subjects to characterize the effect of the dosing of ketoconazole on the the way the body reacts to a dose of GW679769, and to assess the safety profile of oral casopitant with and without ketoconazole.
This study will consist of a screening period, two treatment periods and a post-treatment follow-up visit.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kansas
-
Lenexa, Kansas, United States, 66219
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy male or females
- Females must be of non-childbearing potential
- Adequate organ functions
- Able to swallow and retain oral medications
- Able to understand and comply with study requirements
- Signed ICF
Exclusion Criteria:
- Clinically relevant abnormality identified on the screening exam or any other medical condition or circumstance making the subject unsuitable for participation in the study.
- History of drug or other allergy which contraindicates participation.
- Known immediate hypersensitivity reaction or idiosyncrasy to GW679769 or ketoconazole or drugs chemically related to the study medications.
- Use of an investigational drug within 28 days preceding the first dose of GW679769 or ketoconazole or participation in another clinical trial within the past 30 days.
- Blood donation in excess of 1 pint within 56 days prior to first dose of study medication or intends to donate within 30 days of the post-treatment follow-up visit.
- History of or suspected iron deficiency.
- Positive stool for occult blood.
- Pepsinogen level below the lower limit of laboratory reference range (LLRR).
- Troponin level above 10% of the coefficient of variation of the assay as determined by the laboratory performing the test.
- For male subjects, any history of hypogonadism and treatments associated with hypogonadism including radiation therapy to the testicles.
- For female subjects, a positive serum ß-hCG (beta-human chorionic gonadotropin) pregnancy test.
- Female subject who is lactating.
- Positive urine drug screen (UDS) including alcohol.
- Positive for HIV antibody, hepatitis C antibody or hepatitis B surface antigen
- Positive urinary cotinine. Subjects must not have used any nicotine-containing products, including nicotine patches or gum, within the past 6 months.
- Smoking history = 4 packs per day/year or smoked within the past 12 months.
- History of drug abuse or dependence within the past 6 months.
- History of alcohol abuse within the past 6 months or alcohol consumption in the past 6 months exceeding study requirements
- Presence of uncontrolled nausea & vomiting.
- Presence of an active infection.
- Any degree of heart failure as defined by the New York Heart Association functional classification system.
- Active peptic ulcer disease (PUD) or a history of PUD of unknown etiology.
- Use of any prescription or non-prescription drug(s), herbal or dietary supplements or vitamins within 14 days prior to the first dose of study medication.
- Consumption of any food or drink containing grapefruit or grapefruit juice, apple juice, Seville oranges, kumquats, pomelos or vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi and brussels sprouts, mustard) within 14 days prior to the first dose of study medication.
- History of cholecystectomy or biliary tract disease.
- Any serious or unstable pre-existing medical, psychiatric, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1 Treatment Period 1
Subjects will receive single oral dose of 100 milligram (mg) of Casopitant.
There will be wash out period of 7 days.
|
Casopitant tablets will be available with dose strength of 50 mg.
Subjects will receive two 50 mg tablets for the dose of 100 mg.
On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time
Other Names:
|
Experimental: Cohort 1 Treatment Period 2
Subjects will receive ketoconazole 400 mg once daily on Days 1 - 7. On Day 4 subjects will receive a single dose of oral casopitant 100 mg along with ketoconazole.
|
Casopitant tablets will be available with dose strength of 50 mg.
Subjects will receive two 50 mg tablets for the dose of 100 mg.
On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time
Other Names:
Ketoconazole tablets will be available with dose strength of 200 mg.
The dose of ketoconazole 400 mg will be comprised of two 200 mg tablets.
On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.
|
Experimental: Cohort 2 Treatment Period 1
Subjects will receive single oral dose of 50 mg of Casopitant.
There will be wash out period of 7 days.
|
Casopitant tablets will be available with dose strength of 50 mg and will receive single dose.
On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.
|
Experimental: Cohort 2 Treatment Period 2
Subjects will receive ketoconazole 400 mg once daily on Days 1 - 7. On Day 4 subjects will receive a single dose of oral casopitant 50 mg along with ketoconazole.
|
Ketoconazole tablets will be available with dose strength of 200 mg.
The dose of ketoconazole 400 mg will be comprised of two 200 mg tablets.
On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.
Casopitant tablets will be available with dose strength of 50 mg and will receive single dose.
On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma levels will be measured for casopitant at Period 1: Day 1, 2 & 3.
Time Frame: Period 1: Day 1, 2 & 3
|
Period 1: Day 1, 2 & 3
|
Plasma levels will be measured for casopitant and ketoconazole at Period 2: Day 4, 5, 6, 7, & 8.
Time Frame: Period 2: Day 4, 5, 6, 7, & 8.
|
Period 2: Day 4, 5, 6, 7, & 8.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
clinical lab tests monitoring of International Normalized Ratio (INR) adverse events vital signs 12 lead ECGs liver function tests
Time Frame: throughout the study
|
throughout the study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 20, 2006
Primary Completion (Actual)
January 5, 2007
Study Completion (Actual)
January 5, 2007
Study Registration Dates
First Submitted
November 27, 2006
First Submitted That Met QC Criteria
November 27, 2006
First Posted (Estimate)
November 28, 2006
Study Record Updates
Last Update Posted (Actual)
September 12, 2017
Last Update Submitted That Met QC Criteria
September 11, 2017
Last Verified
September 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Signs and Symptoms, Digestive
- Vomiting
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Antiemetics
- Gastrointestinal Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Neurokinin-1 Receptor Antagonists
- Ketoconazole
- Casopitant
Other Study ID Numbers
- NKV105093
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Study Data/Documents
-
Dataset Specification
Information identifier: NKV105093Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotated Case Report Form
Information identifier: NKV105093Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: NKV105093Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: NKV105093Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: NKV105093Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: NKV105093Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: NKV105093Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nausea and Vomiting, Chemotherapy-Induced
-
GlaxoSmithKlineCompletedChemotherapy-Induced Nausea and Vomiting | Nausea and Vomiting, Chemotherapy-InducedTaiwan, United States, Germany, Russian Federation, Spain, Ireland, Thailand, Hong Kong, Mexico, Philippines, Austria, Chile, Greece, Poland, Canada, Czech Republic, United Kingdom, Hungary, Pakistan, Slovakia, Singapore, Portugal, ... and more
-
Blokhin's Russian Cancer Research CenterRUSSCO/RakFondUnknownChemotherapy-induced Nausea and Vomiting | Nausea | Vomiting | Emesis | Nausea Post ChemotherapyRussian Federation
-
Otolith LabsDrexel University College of MedicineWithdrawnChemotherapy-induced Nausea and Vomiting | Nausea Post ChemotherapyUnited States
-
Indonesia UniversityMashhad University of Medical SciencesRecruitingChemotherapy-induced Nausea and Vomiting | Chemotherapy Effect | Pediatric CancerIndonesia
-
Fudan UniversityNot yet recruitingChemotherapy-induced Nausea and Vomiting | Highly Emetogenic Chemotherapy
-
Joseph MaTerminatedChemotherapy Induced Nausea Vomiting
-
Simon Williamson ClinicHelsinn Healthcare SARecruitingChemotherapy Induced Nausea and VomitingUnited States
-
University of Illinois at ChicagoRecruitingChemotherapy-induced Nausea and VomitingUnited States
-
Albert Einstein College of MedicineJacobi Medical CenterTerminatedChemotherapy-induced Nausea and VomitingUnited States
-
Purdue Pharma, CanadaCompletedChemotherapy-Induced Nausea and VomitingCanada
Clinical Trials on casopitant 100 mg
-
GlaxoSmithKlineCompletedNausea and Vomiting, Chemotherapy-InducedUnited States
-
AstraZenecaCompleted
-
Revogenex, Inc.Suspended
-
NEURALIS s.a.RecruitingPharmacokinetics | SafetyBulgaria
-
CVI PharmaceuticalsUnknown
-
Juventas Therapeutics, Inc.CompletedCritical Limb IschemiaUnited States, India
-
Galapagos NVCompleted
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldRecruiting
-
Medical Centre LeeuwardenGlaxoSmithKlineCompleted
-
University of CreteRecruitingSevere Eosinophilic Asthma w/wo CRSwNPGreece